Myeloid-Derived Suppressor Cells.
Myeloid-Derived Suppressor Cells.
复制标题
DOI：
10.1158/2326-6066.cir-16-0297
复制
发表时间：
2017-01
影响因子：
10.1
通讯作者：
Gabrilovich DI
中科院分区：
文献类型：
--
作者：
Gabrilovich DI
髓系细胞的进化发展是保护宿主的主要机制。它们进化为对抗感染的关键屏障，并且是组织重塑的重要贡献者。然而，在癌症中，骨髓细胞在很大程度上被转化为新的主细胞-肿瘤细胞。这一过程是由骨髓来源的抑制细胞（MDSC）表位。这些细胞与中性粒细胞和单核细胞密切相关。MDSC在健康个体中不存在于稳态，并且出现在与慢性炎症或应激相关的癌症和病理状况中。这些细胞已经成为肿瘤进展的重要贡献者。近年来，大量证据支持MDSC在肿瘤免疫抑制中的关键作用，以及其在肿瘤血管生成、耐药性和促进肿瘤转移中的突出作用。MDSC具有迷人的生物学特性，并参与限制癌症免疫治疗的效果。因此，靶向这些细胞可能是一个有吸引力的治疗机会。
Myeloid cells evolutionary developed as a major mechanism to protect the host. They evolved as a critical barrier against infections and are important contributors to tissue remodeling. However, in cancer, myeloid cells are largely converted to serve a new master – tumor cells. This process is epitomized by myeloid-derived suppressor cells (MDSC). These cells are closely related to neutrophils and monocytes. MDSC are not present at steady state in healthy individuals and appear in cancer and pathological conditions associated with chronic inflammation or stress. These cells have emerged as an important contributor to tumor progression. In recent years, ample evidence supports a key role of MDSC in immune suppression in cancer, as well as their prominent role in tumor angiogenesis, drug resistance, and promotion of tumor metastases. MDSC have a fascinating biology and are implicated in limiting the effects of cancer immunotherapy. Therefore, targeting these cells may represent an attractive therapeutic opportunity.